ProKidney

ProKidney Corp. is a clinical-stage biotechnology company based in Winston-Salem, North Carolina, founded in 2015. The company focuses on developing cell therapy solutions for chronic kidney disease (CKD), aiming to preserve kidney function and reduce the need for dialysis. With a significant number of U.S. adults affected by CKD, ProKidney addresses a critical medical need through its innovative therapies. The lead product candidate, Rilparencel, is an autologous selected renal cell therapy currently undergoing Phase 3 and Phase 2 clinical trials for patients with moderate to severe CKD and diabetes. ProKidney also offers a cryopreserved version of Rilparencel, designed for long-term storage to facilitate broader clinical trial participation. The company emphasizes the use of a patient’s own cells to enhance treatment efficacy and minimize rejection risks. Under the leadership of CEO Bruce Culleton, ProKidney has recently raised $140 million to support its clinical trials and operations. The company is committed to advancing its therapies, particularly for Stage 4 CKD patients, and is actively engaging with regulatory bodies to expedite its development processes.